Flinton Capital Management LLC lowered its stake in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 5.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,800 shares of the medical technology company’s stock after selling 1,360 shares during the quarter. Flinton Capital Management LLC’s holdings in Hill-Rom were worth $2,006,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in HRC. Principal Financial Group Inc. boosted its stake in Hill-Rom by 8.5% during the third quarter. Principal Financial Group Inc. now owns 283,290 shares of the medical technology company’s stock worth $20,963,000 after buying an additional 22,188 shares in the last quarter. Sei Investments Co. boosted its stake in Hill-Rom by 3.6% during the third quarter. Sei Investments Co. now owns 147,197 shares of the medical technology company’s stock worth $10,892,000 after buying an additional 5,127 shares in the last quarter. Retirement Systems of Alabama boosted its stake in Hill-Rom by 7.1% during the third quarter. Retirement Systems of Alabama now owns 119,005 shares of the medical technology company’s stock worth $8,806,000 after buying an additional 7,852 shares in the last quarter. New York State Common Retirement Fund boosted its stake in Hill-Rom by 1.5% during the third quarter. New York State Common Retirement Fund now owns 167,962 shares of the medical technology company’s stock worth $12,429,000 after buying an additional 2,500 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in Hill-Rom by 10.1% during the third quarter. Rhumbline Advisers now owns 141,115 shares of the medical technology company’s stock worth $10,443,000 after buying an additional 12,976 shares in the last quarter. 82.50% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE:HRC traded down $1.73 on Friday, hitting $84.45. The stock had a trading volume of 224,785 shares, compared to its average volume of 406,898. Hill-Rom Holdings, Inc. has a twelve month low of $69.47 and a twelve month high of $91.11. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.29 and a current ratio of 1.75. The company has a market capitalization of $5,588.39, a PE ratio of 20.96, a P/E/G ratio of 1.36 and a beta of 0.97.
Hill-Rom (NYSE:HRC) last issued its earnings results on Friday, January 26th. The medical technology company reported $0.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.13. Hill-Rom had a net margin of 7.14% and a return on equity of 20.24%. The company had revenue of $669.70 million for the quarter, compared to the consensus estimate of $670.00 million. During the same quarter in the previous year, the company earned $0.75 EPS. The firm’s revenue for the quarter was up 5.1% compared to the same quarter last year. analysts forecast that Hill-Rom Holdings, Inc. will post 4.62 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Friday, March 30th. Investors of record on Friday, March 23rd were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.95%. This is a boost from Hill-Rom’s previous quarterly dividend of $0.18. The ex-dividend date of this dividend was Thursday, March 22nd. Hill-Rom’s payout ratio is currently 20.73%.
HRC has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Hill-Rom from a “hold” rating to a “buy” rating and set a $96.00 price target on the stock in a research note on Thursday. Raymond James Financial upgraded shares of Hill-Rom from a “market perform” rating to an “outperform” rating and set a $94.00 price target on the stock in a research note on Wednesday, January 3rd. Goldman Sachs initiated coverage on shares of Hill-Rom in a research note on Wednesday. They set a “neutral” rating and a $85.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $105.00 price target (up previously from $90.00) on shares of Hill-Rom in a research note on Tuesday, January 16th. Finally, KeyCorp reiterated a “buy” rating and set a $97.00 price target on shares of Hill-Rom in a research note on Thursday, January 18th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $93.89.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/08/hill-rom-holdings-inc-hrc-position-trimmed-by-flinton-capital-management-llc.html.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company partners with health care providers across care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: advancing mobility, wound care and prevention, patient monitoring and diagnostics, surgical safety and efficiency and respiratory health.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.